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Background: Mitral stenosis tends to worsen during pregnancy because of the increase in the cardiac output and the heart 
rate. In nonresponders to medical therapy, percutaneous transluminal mitral commissurotomy (PTMC) may be performed when 
there is a suitable valvular anatomy. In this study, we aimed to investigate the clinical and fetal outcomes of pregnant women with 
mitral stenosis who underwent PTMC.
Methods: Thirty-one patients undergoing PTMC during pregnancy were enrolled in this study. The mitral valve area (MVA), 
the transmitral valve mean gradient (MVMG), and the severity of mitral regurgitation were assessed pre- and postprocedurally 
by transthoracic and transesophageal echocardiography. The radiation time was measured during the procedure. The patients 
were followed up during pregnancy, and the neonates were monitored for weight, height, the head circumference, the birth 
Apgar score, and the adverse effects of radiation for at least 12 months.
Results: PTMC was successfully performed on 29 (93.5%) patients. No maternal death or pulmonary edema was reported. 
The mean MVA significantly increased (from 0.73±0.17 cm2 to 1.28±0.24 cm2; P<0.001), and the mean MVMG significantly 
decreased (from 19.62±5.91 mmHg to 8.90±4.73 mmHg; P<0.001) after the procedure. A significant decrease in the systolic 
pulmonary artery pressure was also detected. Mitral regurgitation did not increase in severity in 16 (51.6%) patients. There 
was no significant relationship between the Apgar score, weight, height, and the head circumference at birth and at the 
radiation time.
Conclusion: In our series, PTMC during pregnancy was a safe and effective procedure. Lowering the radiation time with 
low frame-count techniques confers a significant decrease in radiation-related complications.
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Introduction
Valvular heart diseases occur in 2% to 3% of the general 
population, with an increase in prevalence with advancing 
age,1 and complicate 0.5% to 1.5% of all pregnancies.2 
Rheumatic heart diseases with isolated mitral stenosis 
are the dominant cardiac valvular problem in pregnancy.3 
Importantly, mitral stenosis tends to worsen during 
pregnancy because of the increase in the cardiac output and 
the heart rate.4
The principal management for symptomatic patients with 
mitral stenosis during pregnancy concentrates on optimal 
medical therapy such as the use of beta-blockers and also bed 
rest. If medical management fails, balloon valvuloplasty in 
patients with a favorable anatomy might be considered a viable 
option.4 The high fetal and maternal mortality rate (1.8%–
33%) of surgery and the acceptable procedural success of 
percutaneous transluminal mitral commissurotomy (PTMC) 
have made the latter modality a reliable therapy for pregnant 
women.5 Indubitably, PTMC during pregnancy remains 
a high-risk procedure. Apart from the procedural stress 
on the fetus and the potential hemodynamic deterioration 
during the intervention, radiation exposure is another major 
issue. Some of the major nonmalignant effects of ionizing 
radiation on the fetus or the neonate include growth and 
mental retardation, structural disorders, microcephaly, and 
seizure. These complications are not seen at doses lower than 
50 mGy and are expected at doses of 100 mGy and higher.6 
Pregnancy termination should be strongly recommended in 
case of radiation exposure above 10 rads.7
Our center is a tertiary cardiovascular center with long 
experience in performing PTMC. In this study, we sought 
to investigate the clinical and fetal outcomes of pregnant 
women with mitral stenosis who underwent PTMC.
Methods
Between 2010 and 2016, all pregnant women with severe 
rheumatic mitral stenosis referred for PTMC to Rajaie 
Cardiovascular, Medical, and Research Center were included 
in the present study. The eligibility criteria for PTMC were 
comprised of second- or third-trimester pregnancy, severe 
rheumatic mitral stenosis, a mitral valve area (MVA) of 
equal to or smaller than 1 cm², dyspnea on exertion of the 
New York Heart Association Functional Classification 
(NYHA-FC) III or IV despite adequate medical therapy, 
severe hemoptysis, a history of acute pulmonary edema, 
a favorable anatomy according to the Wilkins criteria,4 
mitral regurgitation (MR) of up to moderate severity on 
transesophageal echocardiography (TEE), and the absence 
of clots in the left atrium or the left atrial appendage on TEE.
The patients who did not fulfill the inclusion criteria for 
PTMC were excluded.
The study was approved by the Research and Ethics 
committee of Rajaie Cardiovascular, Medical, and Research 
Center, and informed consent was obtained from all the 
participants.
A comprehensive clinical history was taken to determine the 
symptoms and the NYHA-FC. Additionally, comprehensive 
physical, TEE, and transthoracic echocardiographic 
(TTE) examinations were performed by an expert 
echocardiographer. The MVA, the transmitral valve mean 
gradient (MVMG), and the severity of MR were determined 
in each subject in accordance with the recommendations of 
the American Society of Echocardiography.8
PTMC was performed by experienced interventional 
cardiologists via the Inoue technique.9 The balloon diameter 
for each case was chosen according to the patient’s body 
surface area. Appropriate shielding was used to protect the 
patient’s pelvis and abdomen during the procedure and, thus, 
limit fetal radiation exposure. The procedure was guided by 
TEE and a low frame-count fluoroscopy (7–8 frames per 
second) was selected in order to reduce radiation exposure. 
Radiation status was measured meticulously by a technician, 
who kept the chief operators informed at all times.
TTE was repeated 24 hours after the procedure to evaluate 
the efficacy of the procedure and the following indices: 
the MVA, the MVMG, the severity of MR, the systolic 
pulmonary artery pressure (SPAP), and the presence of 
pericardial effusion or iatrogenic atrial septal defects.
The main criterion for procedural success was defined 
as a decrease in the MVMG to at least half of the baseline 
(preprocedural).4
The maternal outcomes evaluated in the present study 
consisted of procedural success and the presence of maternal 
complications such as pericardial effusion, tamponade, 
death, severe MR, the need for surgical repair, and pulmonary 
edema. On the other hand, the fetal and child outcomes 
recorded in the present analysis comprised the presence of 
intrauterine growth retardation (IUGR), fetal loss, low birth 
weight, microcephaly, failure to thrive (defined as height 
growth below the third percentile for sex), any clinical 
malformation, and developmental delays including speech 
disorders.
Clinical follow-up after hospital discharge was 
accomplished by medical visits 1 month after the discharge, 
and the NYHA-FC of the patients was evaluated. After the 
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first visit, the study population was followed up every 6 
months in terms of maternal and child outcomes.
The newborns’ follow-up data were collected from the 
obstetric documents (for IUGR, the Apgar score, initial 
height, weight, and the head circumference) and the National 
Database for the Health of Newborns and Infants.
After successful PTMC procedures, 5 patients were lost 
to follow-up and were, therefore, analyzed as missing data.
For the statistical analyses, the Kolmogorov–Smirnov 
test was used to test normal distribution. The categorical 
variables were expressed as numbers and percentages and the 
quantitative variables as means±standard deviations (SDs). 
The paired sample t test was utilized for the parametric 
numeric data and the Wilcoxon test for the nonparametric 
numeric data. The correlations between the indices were 
estimated using the Pearson correlation. The IBM SPSS 
Statistics 19.0 for Windows (IBM Corp., Armonk, NY, USA) 
was used for all the statistical analyses. P values less than 
0.05 were considered statistically significant.
Results
The present study recruited 31 patients at a mean age 
of 31.81±4.32 years (min: 23 y, max: 41 y) and a mean 
gestational age of 22.91±6.12 weeks (min: 13 wk, max: 35 
wk). Fifteen (48.4%) patients were in their second trimester 
of pregnancy, and the rest were in their third trimester. Table 
1 depicts the demographic, clinical, and echocardiographic 
data for each patient at baseline.
All the patients had severe mitral stenosis (mean 
MVA=0.73±0.17 cm²) with a mean transvalvular pressure 
gradient of 19.62±5.91 mmHg.
The entire study population had a history of progressive 
dyspnea on exertion of the NYHA-FC III–IV despite medical 
therapy, significant hemoptysis, and/or pulmonary edema.
PTMC was performed successfully in 29 (93.5%) patients. 
The symptoms and impaired functional class were improved 
in all the patients who underwent successful PTMC 
procedures, and none of them experienced the NYHA-FC 
III or IV postprocedurally during the remaining period of 
pregnancy. No postprocedural acute decompensated heart 
failure (pulmonary edema) or maternal mortality was 
detected.
The mean fluoroscopic time during the study was 
97.01±38.82 seconds. The main procedural findings 
are summarized in Table 2. The mean MVA rose by 
0.55±0.11cm2, while the mean MVMG and the mean SPAP 
dropped by 10.74±4.01 mmHg and 25.62±15.41 mmHg, 
respectively.
The degrees of postprocedural MR were as follows: mild 
in 11 (35.5%) patients, mild to moderate in 13 (41.9%), 
moderate in 5 (16.1%), and moderate to severe in 2 (6.5%). 
Table 3 illustrates the pre- and postprocedural MR severity 
in the studied population.
The degrees of MR severity did not increase in more 
than half of the patients (16 cases [51.6%]). However, there 
was a statistically significant rise in MR severity after the 
procedure (P<0.001).
Table 1. Baseline characteristics of the study population*
Maternal age (y) 31.81±4.32
Gestational age (wk) 22.91±6.12
Mean MVA before  PTMC (cm²) 0.71±0.23
Mean transvalvular pressure gradient before PTMC 
(mmHg) 19.62±5.91
*Data are presented as mean±SD
MVA, Mitral valve area; PTMC, Percutaneous transluminal mitral 
commissurotomy
Table 2. Main procedural outcomes of the 31 pregnant women undergoing 
PTMC
Procedural Index Before PTMC After PTMC P
Mean MVA (cm2) 0.73±0.17 1.28±0.24 <0.001
Mean MVMG (mmHg) 19.62±5.91 8.90±4.73 <0.001
SPAP (mmHg) 73.03±22.8 47.4±13.60 <0.001
PTMC, Percutaneous transluminal mitral commissurotomy; MVA, Mitral 
valve area; MVMG, Mitral valve mean gradient; SPAP, Systolic pulmonary 
artery pressure
Table 3. MR severity before and after PTMC 
MR Severity
Before PTMC After PTMC
Frequency Percentage Frequency Percentage
Trivial 4 12.9 - -
Mild 19 61.3 11 35.5
Mild to moderate 6 19.4 13 41.9
Moderate 2 6.5 5 16.1
Moderate to severe - - 2 6.5
MR, Mitral regurgitation; PTMC, Percutaneous transluminal mitral 
commissurotomy 
Two (6.5%) procedures resulted in pericardial effusion and 
tamponade; both of the patients, therefore, underwent closed 
pericardiocentesis. Ultimately, they were discharged alive in 
a good clinical condition.
Two iatrogenic small (5 mm) atrial septal defects were 
detected on TEE within 24 hours of the procedure. These 
2 defects (6.5%) did not have any relationship with the 
radiation time (P=0.251).
There were 3 (11.1%) preterm labors. The etiology was 
identified in 2 patients: gestational diabetes mellitus and 
premature rupture of membranes. None of the preterm labors 
occurred periprocedurally.
Two patients underwent induced abortions. In one of them, 
PTMC was complicated by the chordal rupture of the MV, 
necessitating an induced abortion followed by mitral valve 
replacement (MVR). This was the only patient in the whole 
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study to need surgery. The other patient continued to suffer 
from severe pulmonary hypertension despite a successful 
procedure and a significant drop in the SPAP early after the 
procedure, which was an indication for an induced abortion.
There was 1 (3.2%) case with stillbirth due to IUGR. Twin 
pregnancies were reported in 3 women, for whom the data 
were analyzed as a mean of twins.
As was described previously, in this case series, only 1 
patient was candidated for surgical MVR due to chordal 
rupture. In addition, 5 patients failed to participate in the 
follow-up and 4 pregnancies did not lead to a live neonate. 
Therefore, there were 25 neonates and since 3 pregnancies 
resulted in twins, there were 22 patients for the final analysis.
Birth weights were between 1500 gr and 3600 gr, with 
a mean of 2800.12±592.39 gr. There was no relationship 
between weight at birth and gestational age (P=0.971) or the 
radiation time (P=0.197).
A low birth weight was reported in 9 (33.3%) neonates, 
with 5 of the mothers having undergone PTMC in the second 
trimester and the other 4 in their third trimester. There was 
no significant relationship between a low birth weight and 
gestational age (P=0.601) or the radiation time (P=0.576).
Height at birth was between 45 and 53 cm, with a mean of 
49.04±2.39 cm. The head circumference at birth was between 
32 and 38 cm, with a mean of 34.28±1.67 cm. There was 
no significant relationship between the head circumference 
at birth and the radiation dose (P=0.165) or gestational age 
(P=0.482).
The Apgar score of the second minute after birth was 8 in 4 
(19%) neonates and 9 to 10 (81%) in the rest. In 2 of these 4 
cases with a lower Apgar score, PTMC had been performed 
on the mothers in the second trimester. In these 4 newborns 
with a lower Apgar score, the time of radiation was 100, 65, 
60, and 70 seconds and there was no significant relationship 
between the Apgar score at birth and the radiation time 
(P=0.191).
Weight growth in the first year was below the third 
percentile for sex in 2 (9.1%) cases, between the third and 
the 15th percentiles in 1 (4.5%), between the 50th and the 
85th percentiles in 5 (22.7%), between the 85th and the 97th 
percentiles in 12 (54.5%), and above the 97th percentile in 2 
(9.1%). There was no significant relationship between weight 
growth and the radiation dose (P=0.615) or gestational age 
(P=0.918).
Height growth in the first year was below the third 
percentile for sex in 2 (9.1%) cases, between the third and 
the 15th percentiles in 2 (9.1%), between the 50th and the 
85th percentiles in 3 (13.6%), between the 85th and the 97th 
percentiles in 10 (41.5%), and above the 97th percentile in 
5 (22.7%).
The growth curve for the head circumference in the 
first year was below the third percentile for sex (i.e., 
microcephaly) in 1 (4.5%) case, between the third and 
the 15th percentiles in 1 (4.5%), between the 15th and the 
50th percentiles in 2 (9.1%), between the 50th and the 85th 
percentiles in 5 (22.7%), between the 85th and the 97th 
percentiles in 11 (50%), and above the 97th percentile in 2 
(9.1%). The only case of microcephaly was a twin pregnancy 
and, importantly, both twins showed failure to thrive and the 
head circumference as well as the other growth parameters 
did not improve to 18 months of life. There was no significant 
relationship between the prevalence of microcephaly and 
gestational age (P=1.001) or the radiation time (P=0.391). 
Two children showed failure to thrive according to the 
growth curve (9.1%); one of them was a twin. The rest of the 
children had a normal development over a 12-month period, 
and none of them developed delays in speech and/or seizure.
Discussion
In the present study, we present a report on the outcome 
of PTMC in the pregnant women referred to our center. 
Our series consisted of 31 pregnant women who underwent 
PTMC, with a success rate of 93.5%. The mean fluoroscopic 
time in our study was 97.01±38.82 seconds, which is 
approximately 4.5 times shorter than that in other similar 
studies. In our patients, the MVA, the MMVG, and the SPAP 
decreased significantly. In addition, in all the patients with 
successful PTMC procedures, the symptoms of heart failure 
were completely resolved. During the study, no mortality 
was encountered.
Over the past decade, hospital mortality related to PTMC 
in pregnant women has declined to less than 1%, with 
procedural success rates reported to be as high as 89% to 
100%. The majority of these patients were between 20 and 
30 years of age and in their second trimester of pregnancy 
at the time of PTMC.7 On average, catheter balloon 
commissurotomy increases the MVA to 2.0 cm².10-14 Several 
studies on the role of PTMC in pregnant women have 
reported a twofold increase in the postprocedural MVA (0.8–
1 to 1.2–2.5).5, 10, 12, 15-20 In the majority of these studies, the 
MVA was measured using the Gorlin equation. However, in 
recent works, including our study, the MVA was measured via 
the direct planimetry method using TTE. In a study by Ben 
Farhat et al.,12 the mean MVA by planimetry increased from 
1.07 cm² to 2.32 cm², which is slightly higher than that in our 
study (0.73±0.17 cm² to 1.28±0.24 cm²). The mean MVMG 
in almost all the relevant studies decreased to one-third of 
the procedural value, except in the study by Ben Farhat, 
who reported a decrease in the MVMG from 27 mmHg to 
5 mmHg. In our study, the MMVG exhibited a significant 
decrease (from 19.64±5.96 mmHg to 8.90±4.73 mmHg; 
P<0.001). Additionally, the SPAP significantly decreased 
in our series (from 73.03±22.8 mmHg to 47.4±13.6 mmHg; 
P<0.0001). Similarly, Salehi et al.20 in Madani Center in 
the Iranian city of Tabriz, reported a drop from 58 mmHg 
to 38 mmHg in the SPAP. Our slightly lower MVA might 
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be explained by 2 reasons: firstly, in comparison with other 
studies, our patients had a significantly low MVA before the 
treatment; and secondly, our main goal was to create a bridge 
therapy with the least possible radiation dose, by which both 
mother and fetus would have a safe pregnancy course. An 
MVA higher than 2 cm2 would be ideal but not necessary.
The mean fluoroscopy time was between 5.5 and 9 
minutes in several studies,5, 10-12 while in our study, it was 
approximately 4.5 times shorter (i.e., 97.01±38.82 sec), 
which is below the harmful radiation time. During catheter 
balloon commissurotomy, the radiation exposure to the 
fetus is calculated to be less than 0.2 rad with the use of 
abdominal and pelvic shielding. Adverse effects on the 
fetus are reported to occur with radiation exposures of 
more than 5 rads.7 The shorter duration of radiation in our 
center may be due to its high number of PTMC procedures, 
which has significantly contributed to the experience of the 
interventional cardiologists.
In our case series, we had a 93.5% procedural success rate 
and the symptoms of heart failure were improved in all of 
our patients with successful PTMC procedures. Moreover, 
none of our patients experienced the NYHA-FC III or IV 
after the procedure or during the rest of their pregnancy. A 
study by Steves et al.15 on 71 pregnant women with severe 
symptoms who underwent PTMC showed a 100% success 
rate, with 98% of the patients reaching the NYHA-FC I-II. A 
similarly rapid relief of symptoms was reported by Patel et 
al.16 It is deserving of note that PTMC has a positive effect on 
the quality of life, with symptomatic improvements observed 
in 90% of cases in the immediate post-commissurotomy 
period; this improvement in the hemodynamic profile leads 
to a marked clinical improvement through the remainder 
of pregnancy.12 Fortunately, in the majority of the previous 
studies, the relief of symptoms conferred by PTMC has 
been accompanied by considerably low major complications 
(ranging from 0 to 9%), and it continues to decline as 
expertise in the procedure improves with time.18 In the 
present work, 2 patients were complicated by tamponade and 
1 was candidated for surgical MVR due to chordal rupture. 
Also in 2 patients, non-symptomatic iatrogenic atrial septal 
defects were detected on follow-up imaging. Crucially, no 
maternal mortality occurred in the present study. Previous 
research has demonstrated a low risk of postprocedural 
MR requiring surgical interventions (0–5%) and maternal 
mortality (0.2%).7 In the Norrad and Salehian21 case series 
of 71 pregnant women, there was a 0.2% rate of maternal 
mortality, and 4.6% of the study population needed urgent 
MVR because of severe MR. However, in the study by Ben 
Farhat12 on 44 pregnant women, no maternal or fetal death 
was seen and 1 procedure resulted in severe MR. Elsewhere, 
Routray et al.11 reported 1 case of tamponade and 1 stillbirth.11
No maternal or acute decompensated heart failure 
(pulmonary edema) was seen in our group of patients, and 
only 1 patient was emergently scheduled for surgical MVR 
due to chordal rupture. The rate of maternal death and major 
cardiac events and abortion caused by complications was 
also very low in other studies.5, 9, 16, 20
In our case series, we found 4 preterm labors, 5 pregnancies 
with low birth weights, 3 abortions, and 1 stillbirth due to 
IUGR, which appears to be acceptable in comparison with 
other studies.  Steves et al.15 reported a 13% rate of preterm 
labor in their study. In an investigation by Abdi et al.,5 no 
abortion was detected and 1 stillbirth was reported. Routray 
and colleagues,11 in their analysis of 40 pregnant women 
who underwent PTMC, found no maternal death, abortion, 
or IUGR.
We found no significant relationships between the 
prevalence of microcephaly, low birth weight, the Apgar 
score, growth, failure to thrive, and gestational age and the 
radiation time. All the neonates had a normal development 
over our 12-month follow-up period. In addition, in the 
latter stages, none of the newborns were complicated by 
delays in speech, seizure, or cancer. Abdi et al.5 reported no 
clinical abnormality in the newborns experiencing PTMC in 
their study.  Steves et al.15 reported a normal birth weight 
and a normal growth in 44 months of follow-up in their 
investigation. Similar results were reported by Ben Farhat 
et al.12 in their 12 months of follow-up. Among the relevant 
studies, the longest (17 y) follow-up was done by Gulraze et 
al.,18 who detected a normal growth in all their live neonates. 
In that large case series, nevertheless, the authors reported 
1 stillbirth resulting from obstetric causes, 1 case of sudden 
infant death syndrome, and 1 infantile death at 8 months due 
to pneumonia as infantile mortality.
Conclusion
Our case series showed the safety and efficacy of PTMC 
in pregnant women. Notably, with a considerably lower 
radiation time, we succeeded in attaining good maternal and 
fetal outcomes by comparison with other studies. Therefore, 
in case of severe and critical mitral stenosis during pregnancy, 
PTMC might be considered a valuable bridging therapy with 
a view to protecting both mother and fetus.
Acknowledgments
This study was supported by Rajaie Cardiovascular, 
Medical, and Research Center, Iran University of Medical 
Sciences. 
References
1. Wong MC, Clark DJ, Horrigan MC, Grube E, Matalanis G, 
Farouque HM. Advances in percutaneous treatment for adult 
Ata Firouzi et al. 
The Journal of Tehran University Heart Center 17
J Teh Univ Heart Ctr 14 (1) http://jthc.tums.ac.irJanuary, 2019
TEHRAN HEART CENTER
valvular heart disease. Intern Med J 2009;39:465-474.
2. Glantz JC, Pomerantz RM, Cunningham MJ, Woods JR, Jr. 
Percutaneous balloon valvuloplasty for severe mitral stenosis 
during pregnancy: a review of therapeutic options. Obstet Gynecol 
Surv 1993;48:503-508.
3. Malee MP. Medical and surgical complications of pregnancy. 
In: Scott JR, Gibbs RS, Karlan BY, Haney AF, Danforth DN, 
eds. Danforth's Obstetrics and Gynecology. 9th ed. Philadelphia: 
Lippincott Williams & Wilkins Publishers; 2003. p. 286-300.
4. Warnes CA. Pregnancy and heart disease. In: Mann DL, Zipes 
DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald’s Heart 
Disease: A Textbook of Cardiovascular Medicine. 10th ed. 
Philadelphia: Elsevier Science; 2014. p. 1760-1771.
5. Abdi S, Salehi N, Ghodsi B, Basiri HA, Momtahen M, Firouzi A, 
Sanati HR, Shakerian F, Maadani M, Bakhshandeh H, Chamanian 
S, Chitsazan M, Vakili-Zarch A.  Immediate results of percutaneous 
trans-luminal mitral commissurotomy in pregnant women with 
severe mitral stenosis. Clin Med Insights Cardiol 2012;6:35-39.
6. Shaw P, Duncan A, Vouyouka A, Ozsvath K. Radiation exposure 
and pregnancy. J Vasc Surg 2011;53:28S-34S.
7. Hameed AB, Mehra A, Rahimtoola SH. The role of catheter 
balloon commissurotomy for severe mitral stenosis in pregnancy. 
Obstet Gynecol 2009;114:1336-1340.
8. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 
Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin 
VH, Sundt TM, Thompson A. 2017 AHA/ACC focused update 
of the 2014 AHA/ACC guideline for the management of patients 
with valvular heart disease: a report of the American College of 
Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. J Am Coll Cardiol 2017;70:252-289.
9. Inoue K, Owaki T, Nakamura T, Kitamura F, Miyamoto N. Clinical 
application of transvenous mitral commissurotomy by a new 
balloon catheter. J Thorac Cardiovasc Surg 1984;87:394-402. 
10. Noor-ul-Hadi, Gul AM, Fazal-Ghafoor, Shah ST, Wali A, Shah 
SJ, Shah SS, Ali S, Said R, Kashifulla, Ashraf A, Hafizullah M. 
Radiation exposure in different cardiac catheterization procedures 
in cath lab. J Ayub Med Coll Abbottabad 2013;25:55-57.
11. Routray SN, Mishra TK, Swain S, Patnaik UK, Behera M. Balloon 
mitral valvuloplasty during pregnancy. Int J Gynaecol Obstet 
2004;85:18-23.
12. Ben Farhat M, Gamra H, Betbout F, Maatouk F, Jarrar M, Addad F, 
Tiss M, Hammami S, Chahbani I, Thaalbi R. Percutaneous balloon 
mitral commissurotomy during pregnancy. Heart 1997;77:564-
567.
13. Orrange SE, Kawanishi DT, Lopez BM, Curry SM, Rahimtoola 
SH. Actuarial outcome after catheter balloon commissurotomy in 
patients with mitral stenosis. Circulation 1997;95:382-389.
14. Palacios IF, Sanchez PL, Harrell LC, Weyman AE, Block 
PC. Which patients benefit from percutaneous mitral balloon 
valvuloplasty? Prevalvuloplasty and postvalvuloplasty variables 
that predict long-term outcome. Circulation 2002;105:1465-1471.
15. Esteves CA, Munoz JS, Braga S, Andrade J, Meneghelo Z, Gomes 
N, Maldonado M, Esteves V, Sepetiba R, Sousa JE, Palacios IF. 
Immediate and long-term follow-up of percutaneous balloon mitral 
valvuloplasty in pregnant patients with rheumatic mitral stenosis. 
Am J Cardiol 2006 15;98:812-816.
16. Patel JJ, Mitha AS, Hassen F, Patel N, Naidu R, Chetty S, Pillay R. 
Percutaneous balloon mitral valvotomy in pregnant patients with 
tight pliable mitral stenosis. Am Heart J 1993;125:1106-1109.
17. Ramondo A, Barchitta A, Budano L, Lupia M, Chioin R. Mitral 
valvuloplasty in pregnancy: a report of 4 cases. G Ital Cardiol 
1998;28:873-877. 
18. Gulraze A, Kurdi W, Niaz FA, Fawzy ME. Mitral balloon 
valvuloplasty during pregnancy: the long term up to 17 years 
obstetric outcome and childhood development. Pak J Med Sci 
2014;30:86–90.
19. Martínez-Reding J, Cordero A, Kuri J, Martínez-Ríos MA, Salazar 
E. Treatment of severe mitral stenosis with percutaneous balloon 
valvotomy in pregnant patients. Clin Cardiol 1998;21:659-663.
Percutaneous Transluminal Mitral Commissurotomy in Pregnant Women with Severe Mitral Stenosis 
20. Salehi R, Aslanabadi N, Taghavi S, Pourafkari L, Imani S, Goldust 
M. Percutaneous balloon mitral valvotomy during pregnancy. Pak 
J Biol Sci 2013;16:198-200.
21. Norrad RS, Salehian O. Management of severe mitral stenosis 
during pregnancy. Circulation 2011;124:2756-2760.
